top of page

成人疫苗

首頁 > 疫苗接種 > 成人疫苗

全新B型腦膜炎雙球菌疫苗_thumbnail.jpg
全新 B型腦膜炎雙球菌疫苗

由腦膜炎雙球菌感染之流行性腦膜炎在海外國家例如英國、美國和澳洲的發病率係遠高於香港!這種致命性傳染病在香港每年約有 10-20 名確診個案,死亡率約 10-20%。如選擇移民或海外留學,最好於出發前先諮詢醫生並且考慮接種疫苗預防。而初生嬰兒與幼童屬於較高危一族,都建議接種腦膜炎雙球菌疫苗,加強預防能力!

全新 B型腦膜炎雙球菌疫苗是唯一批準可供10歲以下兒童接種的B型腦膜炎雙球菌疫苗,獲美國FDA及歐盟EMA批準,含有4種抗體,保護更全面!

title_icon.jpg
新冠疫苗接種服務 – 科興
COVID-19 Vaccination Service - Sinovac

仁和體檢為認可疫苗接種中心,現提供科興新冠疫苗接種服務,市民可提前14天於網上預約系統預約。

Contact us via WhatsApp: (+852) 6324 5948 for inquiries and appointments. Please leave your name and availability via WhatsApp. We will respond within a business day.

title_icon.jpg
新冠疫苗接種服務 - 復必泰
COVID-19 Vaccination Service - BioNTech

仁和體檢為認可疫苗接種中心,現提供復必泰新冠疫苗接種服務,市民可提前14天於網上預約系統預約。

Contact us via WhatsApp: (+852) 6324 5948 for inquiries and appointments. Please leave your name and availability via WhatsApp. We will respond within a business day.

新冠疫苗,接種疫苗,健康評估
新冠疫苗,接種疫苗,健康評估
新冠疫苗接種前健康評估
COVID-19 Pre-vaccination Health Assessment

衞生防護中心的指引中列出患有嚴重慢性疾病的人士需延遲接種新冠疫苗,直至病況受控為止,其中包括高血壓、糖尿病及高血脂人士。很多市民平時沒有作定期健康檢查,可能早已患上慢性疾病而不自知,家族有慢性病史的更屬高危一族。醫思健康現正推出「新冠疫苗接種前健康評估」,為有意接種疫苗人士作健康風險評估,並由醫生講解報告。請致電或 WhatsApp 了解更多。

Many citizens do not have regular health checks, unaware of the fact that they may have suffered from chronic diseases, including hypertension, diabetes and hyperlipidaemia. Nevertheless, family history of chronic illnesses makes them a higher risk group.     re:HEALTH is now offering COVID-19 Pre-vaccination Health Assessment and Pre-vaccination Blood Allergy Test for potential vaccine recipients, who will receive a health assessment report explained by the doctor.

15價肺炎結合疫苗, 成人疫苗
15價肺炎結合疫苗, 成人疫苗
15價肺炎結合疫苗
15-valent Pneumococcal Conjugate Vaccine (PCV13)

肺炎球菌有超過100種血清型號,當中尤以血清3型惡菌帶來最大威脅!不論是幼童還是成人,由肺炎球菌感染引起的嚴重及往院個案,大部分都是血清3型肺炎球菌所至。

15價肺炎球菌疫苗已獲美國FDA及歐盟批准使用,在美國、英國、加拿大、澳洲等歐美國家廣泛使用,以預防15種血清型肺炎球菌(1、3、4、5、6A、6B、7F、9V、14、18C、19A、19F、22F、23F、33F)引致的肺炎及入侵性疾病,例如腦膜炎、敗血症等,適用於6週嬰幼兒或以上人士。

PCV15 is effective against both invasive pneumococcal disease and non-invasive pneumococcal pneumonia. While clinical studies indicated that 23vPPV is generally effective in preventing invasive pneumococcal disease, its efficacy against non-invasive pneumococcal pneumonia is suboptimal. Nevertheless, it is worth noting that 23vPPV covers more serotypes and theoretically offers extra protection.

bottom of page